Trial Profile

A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CPI RSV F vaccine-Blue Lake Biotechnology (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions
Sponsors Blue Lake Biotechnology

Most Recent Events

02 Jul 2025 Planned End Date changed from 23 Dec 2024 to 23 Dec 2026.
02 Jul 2025 Planned primary completion date changed from 14 Sep 2024 to 14 Dec 2026.
10 Mar 2025 According to a Blue Lake Biotechnology media release, company announced that it will be presenting safety and immunogenicity data on BLB201 at the 13th International RSV Symposium, occurring March 12-15 in Iguazu, Brazil.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com